France· FR:69002701
PLEGRIDY 63 microgrammes + 94 microgrammes, solution injectable en seringue préremplie
A peginterferon beta-1a product containing péginterféron bêta-1a, registered in France by BIOGEN NETHERLANDS (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Peginterferon beta-1a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB13 (peginterferon beta-1a), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Peginterferon beta-1a · ATC L03AB13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of peginterferon beta-1a costs, country by country.
Normalised to the WHO defined daily dose (8.9 mcg), the median price runs from $1.58 in Czechia to $45.18 in Switzerland — a ×29 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Peginterferon beta-1a · price per daily dose (8.9 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$45.18
- CZ Czechia$1.58
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PÉGINTERFÉRON BÊTA-1A
- Manufacturer
- BIOGEN NETHERLANDS (PAYS-BAS)
- Country
- France (FR)
- ATC code
- L03AB13
- ATC class
- Peginterferon beta-1a
- Defined daily dose
- 8.9 mcg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009279490361 seringue(s) préremplie(s) en verre de 0,5 ml - 1 seringue(s) préremplie(s) en verre de 0,5 mlEUR 475.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
338 interactions on record for peginterferon beta-1a.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Peginterferon beta-1a · interactions on record
338 records
- 15 severe
- 323 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- ClotrimazoleA01AB18moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Peginterferon beta-1a in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPLEGRIDYBiogen Netherlands B.V., Badhoevedorp
- United StatesPlegridyBiogen Inc.
- United KingdomPlegridy 125micrograms/0.5ml solution for injection pre-filled pensBiogen Idec Ltd
- SpainPLEGRIDY 125 microgramos SOLUCION INYECTABLE EN JERINGA PRECARGADA IMBiogen Netherlands B.V.
- FinlandPlegridyBiogen Netherlands B.V.
- BelgiumPlegridy 125 µgBiogen Netherlands
- IcelandPlegridyBiogen Netherlands B.V.
- ItalyPLEGRIDY*1 penna SC 63 mcg 0,5 ml + 1 penna 94 mcg 0,5 mlBIOGEN NETHERLANDS B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Plegridy
- Liechtenstein · Plegridy
- Norway · Plegridy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b44a859e-54d1-4424-aa59-e48bbfcd4aff GET /v1/drugs/b44a859e-54d1-4424-aa59-e48bbfcd4aff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69002701",
"date_amm": "2014-07-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/934",
"substance": "PÉGINTERFÉRON BÊTA-1A",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable et solution injectable",
"voies_administration": "intramusculaire;sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about peginterferon beta-1a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.